The Cedars-Sinai SHI Takotsubo Registry and Proteomic Study is an observational registry that will collect retrospective and prospective demographic, clinical, hemodynamic, laboratory and other diagnostic parameters, therapy and outcome data from individuals who meet the inclusion/exclusion criteria of Takotsubo Registry protocol. Subjects will also be invited to provide a blood sample utilizing a Mitra kit sent to their homes. Researchers from the Barbra Streisand Women's Heart Center will analyze Registry data to identify Takotsubo phenotypes, improve diagnostic capabilities, better predict recurrence rates, and develop targeted Takotsubo treatments.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of participants with Prevalence of the Takotsubo
Timeframe: Baseline, Annual follow-up up to 30years
Number of participants with Recurrence the Takotsubo
Timeframe: Baseline, Annual follow-up up to 30years
Annual update surveys will collect data on patient's prospective health status following Takotsubo event
Timeframe: Baseline, Annual follow-up up to 30years
Risk factors affecting which patients, having had one Takotsubo event, will more likely experience a Takotsubo reoccurrence or related subsequent adverse event
Timeframe: Baseline, Annual follow-up up to 30years